Sbir phase I (nimh topic 3): point-of-care and pharmacy-based antiretroviral drug adherence assays-a quantitative and real-time point-of-care multiplex immunoassay to monitor art/prep medication…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N95025C00010
- Awardee
-
High Throughput Biology Inc. UEI XJMFEHXLB9M5
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $306,100
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20251 · Posted Jul 18, 2024
- Contract value 100% obligated
- $306,100.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Mental Health National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 4 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Short Hills, NJ 07078, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
This is a $306,100 firm-fixed price contract awarded by the National Institute of Mental Health (NIMH), a component of the U.S. Department of Health and Human Services, to High Throughput Biology Inc., a small disadvantaged business concern, under the Small Business Innovation Research (SBIR) Phase I program.
The contract supports the development of a quantitative and real-time point-of-care multiplex immunoassay to monitor adherence to antiretroviral (ART) and pre-exposure prophylaxis (PrEP) medications. This aligns with NIMH's research interests in improving treatment for individuals with HIV/AIDS. The contract has a period of performance through September 29, 2026 and was awarded on a fully small business set-aside basis.
Description
Sbir phase I (nimh topic 3): point-of-care and pharmacy-based antiretroviral drug adherence assays-a quantitative and real-time point-of-care multiplex immunoassay to monitor art/prep medication adherence
Quick answers
Who was awarded contract 75N95025C00010?
75N95025C00010 was awarded to High Throughput Biology Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2025.
How much is contract 75N95025C00010 worth?
The government has obligated $306,100 on 75N95025C00010.
Which agency awarded contract 75N95025C00010?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95025C00010, with funding from National Institute of Mental Health (National Institutes of Health).
Was contract 75N95025C00010 competed?
The extent of competition for 75N95025C00010 was full and open competition after exclusion of sources. The government received 4 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award